PharmAust specialises in the relaunch of existing marketed products for oncology applications making the whole development, regulatory and commercialisation process much faster. In addition, PharmAust's other wholly owned subsidiary, Epichem Pty Ltd generates sales of around $1.7M per annum from contract sales to the pharmaceutical industry of synthetic drugs.
Australischer Marktbericht, 10. Februar 2011 beinhaltet: Calzada (ASX:CZD) kündigt positive Ergebnisse aus Stammzellen-Studie für Knochenwachstum an; Latin Resources Limited (ASX:LRS) erwirbt 14.068 Hektar erstklassige Eisen-und schwere Mineralsand-Gebiete in Peru; Northern Star Resources (ASX:NST) verlautbarten starke Ergebnisse aus Goldproduktion in Western Australia; PharmAust Limited (ASX:PAA) erwirbt hochwertiges Edel-und Basismetalle-Projekt in Europa.
© 2024 ABN Newswire. All Rights reserved.